Weight loss drugs have become an increasingly popular, but controversial, way of quickly shedding extra pounds over the past ...

Recent study show weight loss injections result in greater weight reduction in women than men, with women losing up to 28% of ...

True or False: Pooled trial data showed that rheumatoid arthritis patients taking tofacitinib (Xeljanz) were less likely to ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

COPENHAGEN (Reuters) - Wegovy-maker Novo Nordisk (NYSE: NVO) ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the ...

As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

Novo Nordisk said Jørgensen will remain in his role temporarily to ensure a “smooth transition” while a search for his ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through ...